FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 歸創通橋醫療科技股份有限公司 呈交日期： 2025年9月5日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 H | | | 於香港聯交所上市 | 是 | | | 證券代號 (如上市) | 02190 | 說明 H股 | | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | | 庫存股份變動 | | | | 事件 | | 已發行股份（不包括庫存股份）數 目 | | ...

Core Viewpoint - The company, Gree Chuang Tong Qiao (02190.HK), announced a share buyback on September 4, 2023, spending HKD 2.439 million to repurchase 100,000 shares [1] Group 1 - The total amount spent on the share buyback was HKD 2.439 million [1] - The number of shares repurchased in this transaction was 100,000 [1]

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 第 2 頁 共 7 頁 v 1.3.0 公司名稱： 歸創通橋醫療科技股份有限公司 呈交日期： 2025年9月4日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | H | | 於香港聯交所上市 | 是 | | | 證券代號 (如上市) | 02190 | 說明 | H股 | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | | 庫存股份變動 | | | | | 事件 | 已 ...

Core Viewpoint - The article discusses the upcoming 2025 Shanghai Leading Industries and the 14th Pharmaceutical CEO Forum, highlighting the focus on innovation and global expansion of Chinese pharmaceutical companies [1]. Summary by Sections Event Overview - The event will take place on September 4-5, 2025, at the Mandarin Oriental Hotel in Pudong, Shanghai, featuring nearly a hundred executives from listed companies, including chairpersons, CEOs, and industry leaders [4]. Morning Sessions - The morning session on September 4 will include a keynote speech and several roundtable discussions focusing on topics such as the global expansion of Chinese pharmaceutical companies and the search for the next billion-dollar drug [4][5]. - Notable discussions will include: - "From Local Innovation to Global Leadership: The Era of Chinese Pharmaceutical Companies Going Abroad" [4]. - "The Birth of Big Drugs is the Future of Pharmaceuticals: Finding the Next Billion-Dollar Bomb" [4]. Afternoon Sessions - The afternoon will feature discussions on future disease areas and technologies worth exploring for pharmaceutical assets going abroad, as well as the new cycle of Chinese innovative drugs under global competition [5][6]. - Additional topics will cover advancements in drug development platforms and the emerging field of brain-machine interfaces [6]. TMT Forum - The TMT (Technology, Media, and Telecommunications) forum will also take place, discussing AI's impact on various industries, including gaming and healthcare [7][8]. - Key topics will include AI innovations in mobile internet ecosystems and the future of AI in healthcare [7]. Pharmaceutical Sub-Forum - The pharmaceutical sub-forum will address topics such as ADC technology exploration, probiotic delivery systems, and the future development paths of dual antibodies and XDC [8]. - Discussions will also focus on the integration of medical insurance and the innovative practices in building a multi-level medical security system in China [8].

Core Viewpoint - Guichuang Tongqiao (02190) reported significant growth in its interim results, with a notable increase in revenue and profit, driven by its vascular intervention product lines and international market expansion [1][2]. Financial Performance - The company achieved a revenue of 482 million RMB, representing a year-on-year increase of 31.69% [1]. - Gross profit reached 343 million RMB, up by 31.5% year-on-year [1]. - Shareholder profit attributable to the company was 121 million RMB, marking a 76% increase compared to the previous year [1]. - Basic earnings per share stood at 0.38 RMB [1]. Product Segmentation - 63.3% of the company's revenue came from neurovascular intervention products, while 36.7% was from peripheral vascular intervention products [1]. International Expansion - The company has been actively penetrating the European market, particularly in France, Germany, and Italy, while also exploring emerging markets such as Brazil, India, and South Africa [2]. - International business revenue for the first half of the year reached 15.72 million RMB, reflecting a year-on-year growth of 36.9% [2]. - As of mid-August, the company's overseas revenue had already reached approximately 25 million RMB, surpassing the total overseas revenue of 22.58 million RMB projected for the entire year of 2024, indicating potential for further growth in the second half of the year [2].

Group 1 - The core viewpoint of the news is that Guichuang Tongqiao (02190) has reported significant growth in its interim results, with a notable increase in revenue and profit, driven by its vascular intervention product lines [1][2] - For the six months ending June 30, 2025, the company reported revenue of 482 million RMB, a year-on-year increase of 31.69%, and a gross profit of 343 million RMB, also up by 31.5% [1] - The net profit attributable to shareholders reached 121 million RMB, marking a substantial increase of 76% year-on-year, with basic earnings per share at 0.38 RMB [1] Group 2 - The company’s revenue composition shows that 63.3% comes from neurovascular intervention products, while 36.7% is from peripheral vascular intervention products, indicating a strong performance in both segments [1] - Guichuang Tongqiao has been actively expanding its international presence, particularly in Europe, with successful penetration into markets such as France, Germany, and Italy, as well as emerging markets like Brazil, India, and South Africa [2] - The international business achieved revenue of 15.72 million RMB in the first half of the year, reflecting a year-on-year growth of 36.9%, and is expected to see further acceleration in growth in the second half of the year [2]

归创通桥(02190)发布公告，于2025年9月1日，该公司斥资119.67万港元回购5万股。 ...

Group 1 - The company, Guichuang Tongqiao (02190.HK), announced a share buyback on September 1, 2023, spending HKD 1.197 million to repurchase 50,000 shares [1]

Group 1 - The company, Zhichuang Tongqiao (02190), announced a share buyback plan [1] - The company will spend HKD 1.1967 million to repurchase 50,000 shares [1] - The buyback is scheduled to take place on September 1, 2025 [1]

呈交日期： 2025年9月1日 FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 歸創通橋醫療科技股份有限公司 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | H | | 於香港聯交所上市 | 是 | | | 證券代號 (如上市) | 02190 | 說明 | H股 | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | | 庫存股份變動 | | | | | 事件 | 已發行股份（不包括庫存股份）數 目 | | ...